RESEARCH TRIANGLE PARK, NC – March 27, 2014 – Quintiles today announced that Stella Blackburn, M.B. B.S., has been appointed as the vice president and global head of Risk Management for its Real-World & Late Phase Research group. In this role, Dr. Blackburn will be responsible for leading the group’s risk management efforts in North America, EU and Asia-Pacific. Dr. Blackburn also will develop multidisciplinary benefit risk management services, review and assist customers with interpretation of pharmacovigilance legislation, and ensure compliance with regulations and best practices in the conduct of pharmacovigilance and risk management activities for the company’s real-world and late phase research efforts.
With more than two decades of experience in the pharmacovigilance and pharmacoepidemiology fields, Dr. Blackburn joins Quintiles from the European Medicines Agency (EMA) where she served for more than 16 years in various roles, most recently as the EMA Risk Management Development and Scientific Lead. In this role, Dr. Blackburn was responsible for designing and implementing risk management public policy and processes used throughout Europe. Dr. Blackburn also worked with biopharmaceutical companies, government bodies and industry consortia to advance risk management and real-world research, including registry projects and public-private partnerships.
“Stella’s experience developing innovative risk management solutions for our customers is a tremendous addition to our team,” said Cynthia Verst, M.S., Pharm.D., president, Real-World & Late Phase Research at Quintiles. “Throughout her career, Stella has forged cross-sector partnerships — driving the sort of collaboration we are cultivating here at Quintiles — to develop comprehensive risk management policies and processes designed to protect patients and advance clinical research worldwide. She brings a range of unique safety expertise and experience that we can leverage across our business to better assist our customers with solutions to meet regulatory and reimbursement requirements for their products, and subsequent risk benefit monitoring.”
“I am very excited to be joining Quintiles to lead the global risk management efforts for the company’s Real-World & Late Phase Research group,” said Dr. Blackburn. “Together with my colleagues at Quintiles, I aim to provide best-in-class solutions for real-world and late phase evidence development across the global healthcare system and to further develop risk management practices to benefit patients throughout the world.”
Before joining the EMA, Dr. Blackburn worked in hospital medicine and also spent more than 11 years in the pharmaceutical industry in a variety of leadership roles. Throughout her career, Dr. Blackburn has lectured around the world on pharmacovigilance and risk management and written chapters on the same topic in several textbooks and industry-related guides. Dr. Blackburn is also the past-President of the International Society of Pharmacoepidemiology. Dr. Blackburn trained in medicine at the University of Cambridge and the University of London Guy’s Hospital Medical School. She earned her Master of Science in Epidemiology from the London School of Hygiene and Tropical Medicine.
She is a Fellow of the Royal College of Physicians of Edinburgh, the International Society of Pharmacoepidemiology and the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians in the UK.
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Mari Mansfield, Media Relations (firstname.lastname@example.org)
+ 1.919.998.2639 (office) +1.919.259.3298 (mobile)
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)